

Respiratorius Q3 2022 - One step closer

Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year). The report itself was undramatic, but we see that the positive results from the PK study are positive in terms of partner possibilities for VAL001.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Respiratorius Q3 2022 - One step closer